Lab Manager | Run Your Lab Like a Business

Waters Launches Atlantis™ Premier BEH™ Z-HILIC Column

The new Waters Atlantis™ Column increases the retention of polar-neutral metabolites by two times

Image of the new Atlantis Column on a white background

 The new column features a high retentive ethylene-bridged hybrid.

by Waters
Register for free to listen to this article
Listen with Speechify

For chromatographers performing untargeted metabolite profiling experiments, quantifying all of the polar metabolites in a serum or plasma sample requires a column chemistry that can adequately retain both moderately and highly polar analytes in a single run. Often moderately polar neutral compounds go undetected or elute with matrix interferences in the void; due to inadequate retention on existing commercial HILIC columns. Further complicating matters, certain polar metabolites are phosphorylated or carboxylated causing them to adsorb onto the metal surfaces of stainless-steel columns which means they may never elute from the column so they can be quantified. To work around this problem, chromatographers must condition their column for several hours before they can run their first sample.

Waters has solved both of these issues with the new Waters Atlantis™ Premier BEH™ Z-HILIC Column. The new column features a high retentive ethylene-bridged hybrid (BEH) organic/inorganic zwitterionic HILIC chemistry packed into MaxPeak High Performance Surface (HPS) column hardware. MaxPeak HPS is a new and novel technology that mitigates the unwanted interactions between metal sensitive analytes and the metal ions in the flow path.

The Atlantis™ Premier BEH™ Z-HILIC Column increases the retention of polar-neutral metabolites by two times and obviates the need for lengthy column conditioning protocols. It is available in sub-two -micron, a 2.5 micron and a 5 micron particle sizes.

One chromatographic mode. One column. That’s all it takes for chromatographers to reliably perform more accurate and reproducible polar analyte separations while saving time. For medicinal chemists, this means they can better identify novel pharmacodynamic efficacy and response biomarkers in vivo after the administration of a drug molecule and accelerate the drug development process.